Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 25-29 , July 2010

Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer

  • Michael Pinkawa

      Affiliations

    • Department of Radiation Oncology; and
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany.
    • ,
  • Marc D. Piroth

      Affiliations

    • Department of Radiation Oncology; and
    • ,
  • Richard Holy

      Affiliations

    • Department of Radiation Oncology; and
    • ,
  • Karin Fischedick

      Affiliations

    • Department of Radiation Oncology; and
    • ,
  • Sandra Schaar

      Affiliations

    • Department of Radiation Oncology; and
    • ,
  • Holger Borchers

      Affiliations

    • Department of Urology, RWTH Aachen University, Aachen, Germany
    • ,
  • Axel Heidenreich

      Affiliations

    • Department of Urology, RWTH Aachen University, Aachen, Germany
    • ,
  • Michael J. Eble

      Affiliations

    • Department of Radiation Oncology; and

Received 19 August 2009 ,Revised 21 December 2009 ,Accepted 14 February 2010.

References 

  1. Pound CR, Partin AW, Eisnberger MA, et al. Natural history of progression after PSA evaluation following radical prostatectomy. JAMA. 1999;281:1591–1597
  2. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439
  3. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  4. Pinkawa M, Fischedick K, Piroth MD, et al. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology. 2007;69:129–133
  5. Akyol F, Ozyigit G, Selek U, Karabulut E. PSA bouncing after short term anndrogen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol. 2005;48:40–45
  6. Sengoz M, Abacioglu U, Cetin I, Turkeri L. PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment. Eur Urol. 2003;43:473–477
  7. Mitchell DM, Swindell R, Elliott T, et al. Analysis of prostate-specific antigen bounce after I125 permanent seed implant for localised prostate cancer. Radiother Oncol. 2008;88:102–107
  8. Crook J, Gillan C, Yeung I, et al. PSA kinetics and psa bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007;69:426–433
  9. ASTRO Consensus Panel . Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  10. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG–ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  11. Kovacs G, Potter R, Loch T, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 2005;74:137–148
  12. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988
  13. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  14. Zietman AL, DeSilvio M, Slater JD, et al. Comparison of conventional-dose vs. high-dose radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294:1233–1239
  15. Kuban DA, Levy LB, Tucker SL, et al. Long-term patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of the disease?. Int J Radiat Oncol Biol Phys. 2008;72:S93
  16. Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83:3–10
  17. Ash D, Flynn A, Battermann J, et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000;57:315–321
  18. Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–120
  19. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–1199
  20. Das P, Chen MH, Valentine K, et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys. 2002;54:698–702
  21. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54:450–456
  22. Patel C, Elshaikh MA, Angermeier K, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology. 2004;63:110–113
  23. Zietman AL, Christodouleas JP, Shipley WU, et al. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. Int J Radiat Oncol Biol Phys. 2005;62:714–718

PII: S0167-8140(10)00103-9

doi: 10.1016/j.radonc.2010.02.010

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 25-29 , July 2010

Article Tools

* Image Usage & Resolution